SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Investigation Report on China Montelukast Market

DUBLIN, March 25, 2014 /PRNewswire/ --

Research  and  Markets (http://www.researchandmarkets.com/research/rq8jml/investigation) has announced the addition of the "Investigation Report on China Montelukast Market" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

There are over 30 million people suffering from seasonal asthma of different levels worldwide, and the situation is worse in deeply contaminated countries and regions with high tobacco consumption. Asthma and allergic rhinitis are both very common diseases in the world today. As the atmosphere becomes more seriously contaminated, incidence of these diseases increases year by year.

Montelukast, developed by MSD Co., Ltd., is widely used in curing allergic rhinitis and asthma. Montelukast is a CysLT1 antagonist that blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the broncho-constriction otherwise caused by the leukotriene and results in less inflammation.

In 1998, montelukast sodium tablets (10mg) and chewable tablets (5mg) were approved by FDA to the market with the trade name ""Singulair"". In 2000 and 2002, montelukast chewable tablets (4mg) and montelukast granules (4mg) were approved to the market in turn. They are mainly used in prevention and long-term treatment of asthma of adult and children aged two and above.

Patent of Singulair in U.S. expired on August 3, 2012. Hereafter, FDA approved over 10 manufacturers' applications for their generic drugs to the market. Among them, Teva Pharmaceutical Industries Limited launched tablets, chewable tablets and oral granules while Dr. Reddy's Laboratories Ltd. launched tablets and chewable tablets. In 2012, due to the generic drug intrusion, sales revenue of Singulair produced by MSD Co., Ltd. dropped to USD 3,853 million, decreased by 30%.

In 1999, montelukast chewable tablets (5mg) and tablets (10mg) produced by MSD Co., Ltd. were allowed to enter China with the trade name ""Singulair"". Hereafter, montelukast chewable tablets (4mg) and granules (4mg) were permitted into Chinese market sequentially. Generic montelukast tablets (10mg) and chewable tablets (5mg) produced by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to the market in 2006 with the trade name ""Bai Sanping"". Mudanjiang Hengyuan Pharmaceutical Co., Ltd. was the first manufacturer that acquired approval of montelukast sodium raw material production in 2006. In 2008, Lunan Better Pharmaceutical Co., LTD. was given the approval of montelukast tablets (10mg) and chewable tablets (5mg). In addition, many drug manufacturers such as YZJ Group and Beijing Winsunny Pharmaceutical Company Limited have applied for generic drugs production.


Key  Topics  Covered:

1 Relevant Concepts of Montelukast

2 Market Overview of Montelukast in China

3 Investigation on Sales Value of Montelukast in China, 2009-2013

4 Investigation on Market Share of Major Montelukast Manufacturers in China, 2009-2013

5 Investigation on Market Size of Montelukast by Dosage Form in China, 2009-2013

6 Reference Price of Montelukast Produced by Different Enterprises in China Hospital Market, 2013

7 Analysis on Major Montelukast Manufacturers in China, 2009-2013

8 Prospect of China Montelukast Market, 2014-2018


Companies  Mentioned:

  • MSD (UK)
  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)


For more information visit http://www.researchandmarkets.com/research/rq8jml/investigation


Media  Contact: Laura Wood , +353-1-481-1716, [email protected]


SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.